Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19320604 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | September 2025 | February 2026 | Allow | 5 | 1 | 1 | No | No |
| 18586021 | PYRROLO[3,2-C][2,6]NAPHTHYRIDINE-2-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORS | February 2024 | October 2024 | Allow | 8 | 1 | 1 | No | No |
| 18586070 | PYRROLO[3,2-C][2,6]NAPHTHYRIDINE-2-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORS | February 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18433196 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | February 2024 | September 2024 | Allow | 7 | 0 | 1 | Yes | No |
| 18430134 | 1-CYCLOPROPYL-6-FLUORO-7-(4-((5-(4-METHOXYBENZYLIDENEAMINO)-2-THIOXO-1,3,4- THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3- CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUND | February 2024 | April 2024 | Allow | 3 | 0 | 0 | No | No |
| 18430131 | 1-CYCLOPROPYL-6-FLUORO-7-(4-((5-(4-METHOXYBENZYLIDENEAMINO)-2-THIOXO-1,3,4- THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3- CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUND | February 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18430138 | 1-CYCLOPROPYL-6-FLUORO-7-(4-((5-(4-METHOXYBENZYLIDENEAMINO)-2-THIOXO-1,3,4- THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3- CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUND | February 2024 | October 2024 | Abandon | 9 | 0 | 0 | No | No |
| 18404967 | COMBINATION TREATING PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD | January 2024 | October 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18390829 | EYE DROPS TO TREAT CHEMICALLY INDUCED CORNEAL DAMAGE | December 2023 | September 2025 | Allow | 21 | 2 | 1 | Yes | No |
| 18569434 | ISOQUINOLINE ALKALOID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | December 2023 | August 2025 | Abandon | 20 | 2 | 1 | Yes | No |
| 18389456 | AGONISTS OF EPHA AND THEIR USES | November 2023 | June 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18507797 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | November 2023 | January 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18495721 | 5-(SUBSTITUTEDPHENYL)-7-IMINO-7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTI-INFLAMMATORY AGENTS | October 2023 | September 2024 | Allow | 11 | 1 | 1 | No | No |
| 18492627 | AMINONAPHTHOQUINONE COMPOUNDS FOR TREATMENT AND/OR PREVENTION OF FIBROSIS DISEASES | October 2023 | June 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18484116 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | October 2023 | April 2025 | Allow | 19 | 2 | 1 | No | No |
| 18373067 | CDK INHIBITORS | September 2023 | September 2024 | Abandon | 11 | 1 | 1 | No | No |
| 18373060 | CDK INHIBITORS | September 2023 | September 2024 | Abandon | 11 | 1 | 1 | No | No |
| 18369782 | 7-(4-((5-(2-CHLOROBENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY COMPOUND | September 2023 | March 2024 | Allow | 6 | 1 | 1 | No | No |
| 18241498 | 1-CYCLOPROPYL-6-FLUORO-7-(4-((5-(4-METHOXYBENZYLIDENEAMINO)-2-THIOXO-1,3,4- THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3- CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUND | September 2023 | January 2024 | Allow | 4 | 1 | 1 | No | No |
| 18237441 | PYRROLO[3,2-c][2,6]NAPHTHYRIDINE-2-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORS | August 2023 | February 2024 | Allow | 5 | 2 | 1 | No | No |
| 18235054 | PYRIDO[3',4':4,5]PYRROLO[2,3-C]ISOQUINOLINE COMPOUNDS AS CK2 INHIBITORS | August 2023 | January 2024 | Allow | 5 | 1 | 1 | No | No |
| 18231957 | FRAGRANCES WITH NOTE OF LILY OF THE VALLEY | August 2023 | October 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18232182 | 5-(SUBSTITUTEDPHENYL)-7-IMINO-7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTI-INFLAMMATORY AGENTS | August 2023 | November 2023 | Allow | 3 | 0 | 1 | Yes | No |
| 18226333 | TREATMENT OF SCLERODERMA AND RAYNAUD'S SYNDROME | July 2023 | February 2025 | Abandon | 19 | 2 | 1 | No | No |
| 18343792 | New Combination of active agents for the treatment of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) | June 2023 | May 2024 | Allow | 11 | 0 | 0 | No | No |
| 18199624 | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | May 2023 | August 2024 | Abandon | 15 | 2 | 1 | No | No |
| 18309948 | Amino Pyrimidine Derivatives | May 2023 | December 2025 | Abandon | 32 | 2 | 1 | No | No |
| 18299511 | CANNABINOID DERIVATIVES AND THEIR USE | April 2023 | February 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18187141 | MACROCYCLIC MUSK LACTONES AND USES THEREOF | March 2023 | October 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18021916 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES COMPRISING ABEMACICLIB AS ACTIVE INGREDIENT | February 2023 | February 2026 | Abandon | 36 | 1 | 0 | Yes | No |
| 18169734 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | February 2023 | March 2025 | Allow | 25 | 2 | 1 | No | No |
| 18021189 | ALCOHOL-BASED DISINFECTANT FOAM | February 2023 | March 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18021282 | Compound, Aldehyde Dehydrogenase 2 Activating Agent, Pharmaceutical Composition, and Therapeutic and/or Prophylactic Drug | February 2023 | September 2025 | Allow | 31 | 0 | 1 | Yes | No |
| 18168221 | PHARMACEUTICAL FORMULATIONS FOR TREATING ENDOMETRIOSIS, UTERINE FIBROIDS, POLYCYSTIC OVARY SYNDROME OR ADENOMYOSIS | February 2023 | February 2024 | Allow | 12 | 1 | 1 | No | No |
| 18041415 | ANALGESIC AGENT | February 2023 | March 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18101951 | POLYMORPHS AND SOLID FORMS OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO)PROPANAMIDE, AND METHODS OF PRODUCTION | January 2023 | May 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 18001539 | SYNTHESIS OF (2S,5R)-5-(2-CHLOROPHENYL)-1-(2'-METHOXY-[1,1'-BIPHENYL]-4- CARBONYL)PYRROLIDINE-2-CARBOXYLIC ACID | December 2022 | September 2025 | Allow | 33 | 0 | 1 | Yes | No |
| 18000504 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | December 2022 | March 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17983388 | COMPOSITIONS AND METHODS FOR POST-OPERATIVE OCULAR CARE | November 2022 | December 2024 | Abandon | 26 | 2 | 0 | No | Yes |
| 17982846 | METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED AlphaV INTEGRIN ANTAGONISTS | November 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17982182 | Heterodimers of Glutamic Acid | November 2022 | December 2025 | Allow | 37 | 2 | 0 | No | Yes |
| 17997978 | METHOD TO TREAT VIRAL INFECTION INDUCED BY A CORONAVIRUS | November 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17922804 | CDK INHIBITORS | November 2022 | March 2025 | Allow | 29 | 1 | 1 | Yes | No |
| 18050351 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | October 2022 | April 2024 | Allow | 18 | 0 | 1 | Yes | No |
| 17996892 | NOVEL COMPOUND [2-(DIMETHYLAMINO)-2-PHENYLBUTYL]-3,4,5-TRIMETHOXYBENZOATE 4-METHYL-2H-CHROMEN-2-ON-7-YL SULPHATE AND USE THEREOF | October 2022 | July 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 18046194 | Identification of oleanolic acid and plant extract for glucose-6-phosphate dehydrogenase-related disorders including Bag3opathy | October 2022 | March 2025 | Allow | 29 | 1 | 1 | Yes | No |
| 17916855 | Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder | October 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17937450 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | October 2022 | August 2023 | Allow | 11 | 0 | 1 | Yes | No |
| 17995143 | ISOQUINOLINE DERIVATIVES FOR USE IN THERAPY | September 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17864208 | ISOTRETINOIN FORMULATIONS AND USES AND METHODS THEREOF | July 2022 | December 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17811914 | Combination of active agents for the treatment of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) | July 2022 | March 2023 | Allow | 9 | 0 | 0 | No | No |
| 17855604 | DOSAGE FORMS OF ROFECOXIB AND RELATED METHODS | June 2022 | October 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17849217 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REPROGRAMING IMMUNE ENVIRONMENT IN A SUBJECT IN NEED THEREOF | June 2022 | February 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17845278 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | June 2022 | September 2025 | Abandon | 39 | 3 | 0 | Yes | Yes |
| 17783336 | 6-SUBSTITUTED, 22-CYANO HYODEOXYCHOLANIC ANALOGUES AND USES THEREOF | June 2022 | November 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17828297 | PYRAZOLINE-DERIVED COMPOUND FOR USE IN THE PREVENTION AND/OR TREATMENT OF PAIN AND INFLAMMATION ASSOCIATED TO SURGERY IN MAMMALS | May 2022 | December 2024 | Allow | 30 | 3 | 0 | Yes | No |
| 17747948 | TREATMENT OF CANCER WITH SMG1-INHIBITORS | May 2022 | June 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17746796 | COMPOSITIONS AND METHODS FOR TREATING ECZEMA | May 2022 | November 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17745024 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | May 2022 | November 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17721916 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | April 2022 | July 2023 | Allow | 15 | 0 | 1 | No | No |
| 17721067 | BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS-CLOVES SYNDROME) | April 2022 | April 2025 | Allow | 36 | 3 | 1 | Yes | No |
| 17701884 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHOROIDAL NEOVASCULARISATION | March 2022 | January 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17690872 | MACROCYCLIC MUSK LACTONES AND USES THEREOF | March 2022 | January 2023 | Allow | 11 | 1 | 1 | No | No |
| 17682205 | METHOD FOR TREATING HYPERHIDROSIS | February 2022 | January 2026 | Abandon | 46 | 1 | 0 | No | No |
| 17582945 | PARENTERAL ESMOLOL FORMULATION | January 2022 | December 2023 | Allow | 23 | 1 | 0 | No | No |
| 17548550 | Compositions And Methods For Treating Nicotine-Related Disorders And Symptoms Using Dihydromyricetin | December 2021 | May 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17457808 | PYRAZOLYL AND PYRIMIDINYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | December 2021 | July 2023 | Allow | 19 | 0 | 1 | Yes | No |
| 17537435 | EFFLUX INHIBITOR COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME | November 2021 | October 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17526405 | USE OF ANTAGONISTS AND/OR INVERSE AGONISTS OF CB1 RECEPTORS FOR PREPARING MEDICAMENTS FOR TREATING FATIGUE POST-VIRAL FATIGUE SYNDROME | November 2021 | October 2023 | Allow | 23 | 2 | 1 | No | No |
| 17524942 | COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES | November 2021 | September 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17513281 | NOVEL DOSAGE FORMS OF ROFECOXIB AND RELATED METHODS | October 2021 | October 2023 | Abandon | 23 | 4 | 0 | No | No |
| 17508054 | Amino Pyrimidine Derivatives | October 2021 | January 2023 | Allow | 15 | 0 | 0 | No | No |
| 17442650 | HPK1 INHIBITORS | September 2021 | April 2025 | Allow | 43 | 0 | 1 | Yes | No |
| 17441355 | COMBINATIONS USEFUL IN A METHOD FOR TREATING SARCOMA | September 2021 | March 2025 | Allow | 42 | 2 | 0 | No | No |
| 17435819 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | September 2021 | July 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17431591 | NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME | August 2021 | November 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17428976 | COMBINATION THERAPY FOR TREATMENT OF BRAIN DISORDERS | August 2021 | January 2026 | Abandon | 53 | 2 | 1 | No | No |
| 17395357 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | August 2021 | October 2024 | Allow | 38 | 3 | 1 | Yes | No |
| 17389449 | Novel therapeutic agent for inflammatory disease | July 2021 | August 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17375796 | Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin | July 2021 | September 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17358883 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | June 2021 | December 2023 | Allow | 30 | 2 | 1 | No | No |
| 17415376 | USE OF A PAR-1 ANTAGONIST FOR THE TREATMENT OF A CHRONIC INFLAMMATORY INTESTINAL DISEASE | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17415065 | TREATMENT OF GASTROINTESTINAL DISORDERS AND SYMPTOMS THEREOF | June 2021 | March 2026 | Abandon | 57 | 3 | 1 | No | No |
| 17414696 | RAPAMYCIN DERIVATIVES | June 2021 | December 2024 | Allow | 42 | 0 | 1 | Yes | No |
| 17413101 | COMPOSITION FOR PREVENTING OR TREATING CELLULAR SENESCENCE-ASSOCIATED DISEASES, CONTAINING HOMOHARRINGTONINE AS ACTIVE INGREDIENT | June 2021 | April 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17331803 | LIQUID LAUNDRY PRODUCT COMPRISING A FRAGRANCE COMPOSITION COMPRISING ISOPULEGOL | May 2021 | April 2025 | Allow | 47 | 4 | 1 | Yes | No |
| 17325468 | COMBINATION TREATING PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD | May 2021 | July 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17324258 | Synthesis of Ibuprofen Hybrid Conjugates as Anti-Inflammatory and Analgesic Agents | May 2021 | August 2023 | Allow | 27 | 2 | 1 | Yes | No |
| 17320882 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | May 2021 | May 2023 | Abandon | 24 | 3 | 1 | Yes | No |
| 17316643 | NEOSTIGMINE COMBINATION AND COMPOSITIONS | May 2021 | September 2025 | Abandon | 52 | 4 | 1 | No | No |
| 17242317 | 9,11-SECOSTEROIDS AND THE USE OF 9,11-SECOSTEROIDS IN PREPARING PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INFLAMMATION | April 2021 | February 2025 | Allow | 46 | 4 | 1 | No | No |
| 17239196 | INHIBITION OF CATALYTIC SITE COMMON TO MULTIPLE 3 ALPHA-OXIDOREDUCTASES FOR TREATMENT OF PROSTATE CANCER | April 2021 | September 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17238535 | HETERODIMERS OF GLUTAMIC ACID | April 2021 | September 2022 | Abandon | 17 | 2 | 1 | No | No |
| 17211121 | HETEROCYCLIC DIAMIDINES | March 2021 | April 2025 | Abandon | 49 | 3 | 1 | Yes | No |
| 17279107 | APPLICATION OF CHIGLITAZAR AND RELATED COMPOUNDS THEREOF | March 2021 | November 2025 | Abandon | 56 | 3 | 1 | No | No |
| 17182728 | NOVEL DOSAGE FORMS OF ROFECOXIB AND RELATED METHODS | February 2021 | May 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17178217 | CGRP ANTAGONISTS FOR TREATING MIGRAINE BREAKTHROUGH | February 2021 | January 2024 | Abandon | 35 | 5 | 1 | No | No |
| 17169371 | LIPID PRODRUGS OF NEUROSTEROIDS | February 2021 | January 2023 | Abandon | 23 | 2 | 1 | No | Yes |
| 17156233 | CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION | January 2021 | May 2025 | Abandon | 52 | 6 | 1 | Yes | No |
| 17155390 | Synergistic Compositions for Gynecological Procedures | January 2021 | August 2024 | Abandon | 43 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RODRIGUEZ, RAYNA B.
With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner RODRIGUEZ, RAYNA B works in Art Unit 1628 and has examined 576 patent applications in our dataset. With an allowance rate of 31.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner RODRIGUEZ, RAYNA B's allowance rate of 31.9% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by RODRIGUEZ, RAYNA B receive 2.96 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by RODRIGUEZ, RAYNA B is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +26.3% benefit to allowance rate for applications examined by RODRIGUEZ, RAYNA B. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 9.1% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 16.1% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 51.4% of appeals filed. This is in the 22% percentile among all examiners. Of these withdrawals, 51.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 67.3% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 57% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.2% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.